What is Navitoclax ABT-263 ?

Navitoclax, also known as ABT-263 or ABT263, is a potent and orally active inhibitor of the Bcl-2 protein family. It acts on Bcl-xL, Bcl-2, and Bcl-w with Ki values of ≤ 0.5 nM, ≤ 1 nM, and ≤ 1 nM, respectively. Navitoclax has anti-tumor activity against various cells, such as H146, H82, H889, H1963, and H1417, and causes in vivo tumor regression. Moreover, Navitoclax can enhance the therapeutic effect of chemotherapy drugs.

Basic Information

Product Name: Navitoclax(ABT-263)

CAS: 923564-51-6

MF: C47H55ClF3N5O6S3

MW: 974.61

MDL No.:MFCD12756219

Appearance: white solid

Purity: 99%+

Package: 1g; 5g; 100g

MOQ: 1g

Origin: China

Used: lab research

Stability: Stable

Delivery Time: 3-7days

Structural formula:

Technical Specification:

Biological activity

Navitoclax ABT-263 is an effective inhibitor of Bcl-xL, Bcl-2, and Bcl-w, with Ki values of ≤ 0.5 nM, ≤ 1 nM, and ≤ 1 nM in cell-free assays, respectively, but with weak binding to Mcl-1 and A1

What is the function of Navitoclax (ABT-263)?

ABT-263 is a small molecule drug that works for inhibiting B-cell lymphoma 2 (Bcl-2) family proteins, which play a key role in the survival of cancer cells. By blocking these proteins, it induces cell death in cancer cells and enhances the effectiveness of chemotherapy.

Navitoclax is currently used in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), two types of blood cancers that typically affect adults. When used in combination with chemotherapy, it has been shown to improve response rates and overall survival in patients with these types of cancer.

Additionally, it is being investigated for its potential use in the treatment of other types of cancer, including non-small cell lung cancer and ovarian cancer.

However, it can cause some side effects, such as thrombocytopenia (low platelet count), which can increase the risk of bleeding. Therefore, patients receiving it may require platelet transfusions to manage this side effect.

Overall, ABT263 has shown promising results in the treatment of CLL, SLL, and other types of cancer. It represents a new approach to cancer therapy that targets the fundamental mechanisms that allow cancer cells to survive and grow.

What is the Application of Navitoclax (ABT-263)?

Navitoclax is a cancer drug that has gained a lot of attention in recent years due to its potential in treating various cancers. The drug has been developed by Abbott Laboratories and Genentech and has been approved by the FDA for use in combination with other cancer medications.

The main application of ABT263 is in the treatment of hematological cancers such as chronic lymphocytic leukemia (CLL) and lymphoma. The drug works by inhibiting the activity of proteins called B-cell lymphoma 2 (BCL-2) and B-cell lymphoma-extra-large (BCL-xL), which are present in many blood cancers. By inhibiting these proteins, it induces cell death and prevents the cancer cells from growing and spreading.

Apart from hematological cancers, it is also being studied for its potential in treating solid tumors such as lung, breast, and ovarian cancers. In preclinical trials, the drug has shown promising results in reducing the size of solid tumors and inhibiting their growth.

It has some side effects, including low platelet counts, nausea, and fatigue. However, with proper monitoring and management, these side effects can be controlled, and the drug can be safely used to treat cancer.

In conclusion, Navitoclax ABT-263 is a novel cancer drug that has the potential to revolutionize cancer treatment. Its ability to inhibit BCL-2 and BCL-xL proteins makes it an effective treatment option for hematological cancers, and its potential in treating solid tumors is being studied extensively. Despite some side effects, the drug can be safely used with proper monitoring. With further research and development, it could prove to be a valuable asset in the fight against cancer.

Packing & Shipping

Payment Term

Why Choose Xi'an Yihui?Customer feedback

Xi'an Yihui certificates

Welcome to Xi'an Yihui Factory

Our Advantage

Rich experience: we have 13 Years of professional experience;

Customers all over the world: sell to more than 100 countries;

Provide diversified products: the products have been applied to all major international brands in the fields of drugs, dietary supplements, cosmetics, animal nutrition and functional food.

Price advance: low MOQ with competitive price;

Quality certification: ISO; Halal; Kosher certified

After-sales service: Professional team 7*24 hours customer service.

Contact Us:

Yihui company takes pride in being a reliable ABT-263 manufacturer and supplier. Our commitment to quality and conformity to international standards is underscored by our ISO, Kosher, and Halal certifications. For inquiries or to place an order, contact us immediately at sales@yihuipharm.com.